In this issue:
Antibiotics and biologic persistence in psoriasis
Vilobelimab for moderate-to-severe hidradenitis suppurativa
Eltrekibart in adults with hidradenitis suppurativa
Reactivation of HBV and HCV after biologics and tsDMARDs
Originator vs biosimilar adalimumab in hidradenitis suppurativa
Sex differences in biologic response and persistence in psoriatic arthritis
Risankizumab super responders in moderate-to-severe psoriasis
Nemolizumab in patients with prurigo nodularis
Risankizumab in genital or scalp psoriasis
Secukinumab + upadacitinib for hidradenitis suppurativa with immune-related comorbidities
Please login below to download this issue (PDF)